However, in the field of sarcoma, there are still some problems that need to be solved, such as whether PD-1/PD-L1 inhibitors combined with other treatments can improve the efficacy compared with PD-1/PD-L1 inhibitor monotherapy, whether there is a difference in the efficacy of combined chemotherapy or combined targeted therapy, and whether adverse events are related to prognosis. Here, CD274 is linked to sarcoma.